These results highlight the potential of developing the scFv clones for laboratory or clinical uses, either as a diagnostic tool or a therapeutic candidate for combination or drug conjugation to target nectin-4-positive cancers, including breast cancer. This evidence concerns the gene NECTIN4 and breast carcinoma.